Cladribine as a therapeutic option in multiple sclerosis

被引：10

作者：

Warnke, Clemens ^{[1
]}

Leussink, Verena I. ^{[1
]}

Goebels, Norbert ^{[1
]}

Aktas, Orhan ^{[1
]}

Boyko, Alexey ^{[2
,3
]}

Kieseier, Bernd C. ^{[1
]}

Hartung, Hans-Peter ^{[1
]}

机构：

[1] Univ Dusseldorf, Dept Neurol, Fac Med, D-40225 Dusseldorf, Germany

[2] Russian State Med Univ, Dept Neurol & Neurosurg, Moscow 117437, Russia

[3] Moscow MS Ctr, Moscow, Russia

来源：

CLINICAL IMMUNOLOGY | 2012年 / 142卷 / 01期

关键词：

Cladribine; Multiple sclerosis; Immunosuppressant; Oral drugs; DOUBLE-BLIND; 2-CHLORODEOXYADENOSINE; TOXICITY; 2-CHLORO-2'-DEOXYADENOSINE; APOPTOSIS; TABLETS; SAFETY; CELLS; TRIAL;

D O I：

10.1016/j.clim.2011.05.009

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral cladribine have recently been published. However, benefits need to be weighed against potential risks to define the role of this compound within current treatment regimens. Here we review present data on efficacy of oral cladribine and discuss known and anticipated risks of this drug. (C) 2011 Published by Elsevier Inc.

引用

页码：68 / 75

页数：8

共 50 条

[31] Cladribine: An Investigational immunomodulatory agent for multiple sclerosis
Brousil, Julie A.
Roberts, Russel J.
Schlein, Amanda L.
ANNALS OF PHARMACOTHERAPY, 2006, 40 (10) : 1814 - 1821
[32] Oral Cladribine and Fingolimod for Relapsing Multiple Sclerosis
Li, Haifeng
Zhang, Xu
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (18): : 1738 - 1739
[33] Cladribine personalised dosing to treat multiple sclerosis
Mao, Z.
Alvarez-Gonzalez, C.
Allen-Philbey, K.
Turner, B.
Gnanapavan, S.
Marta, M.
Mathews, J.
Giovannoni, G.
Baker, D.
Schmierer, K.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 609 - 609
[34] Cladribine - A review of its use in multiple sclerosis
Langtry, HD
Lamb, HM
BIODRUGS, 1998, 9 (05) : 419 - 433
[35] Cladribine to Treat Relapsing Forms of Multiple Sclerosis
Gavin Giovannoni
Neurotherapeutics, 2017, 14 : 874 - 887
[36] Development of oral cladribine for the treatment of multiple sclerosis
Hans-Peter Hartung
Orhan Aktas
Bernd Kieseier
Giancarlo Comi
Journal of Neurology, 2010, 257 : 163 - 170
[37] Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine
Biernacki, Tamas
Sandi, Daniel
Bencsik, Krisztina
Vecsei, Laszlo
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2020, 20 (04) : 269 - 285
[38] The treatment of chronic progressive multiple sclerosis with cladribine
Beutler, E
Sipe, JC
Romine, JS
Koziol, JA
McMillan, R
Zyroff, J
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (04) : 1716 - 1720
[39] PERSONALISED DOSING OF CLADRIBINE TO TREAT MULTIPLE SCLEROSIS
Mao, Zhifeng
Alvarez-Gonzalez, Cesar
Allen-Philbey, Kimberley
Mathews, Joela
Turner, Benjamin P.
Gnanapavan, Sharmilee
Marta, Monica
Baker, David
Giovannoni, Gavin
Schmierer, Klaus
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A47 - A48
[40] Clinical practice experience with cladribine in multiple sclerosis
Meca-Lallana, V.
Aguirre, C.
Torres, J.
Diaz, C.
Del Rio, B.
Martin, R.
Vivancos, J.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 138 - 139

← 1 2 3 4 5 →